Zalutumumab clinical trials
Also written HuMax-EGFr.
How each study uses zalutumumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 1
Studies
Open first, then newest update. How each study uses zalutumumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedPhase 1/2GenmabNCT01054625Written as zalutumumabHow we know
- Zalutumumab in Non-curable Patients With SCCHNCompletedPhase 2GenmabNCT00542308Written as ZalutumumabHow we know
- Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based ChemotherapyTerminatedPhase 1/2GenmabNCT00707655Written as ZalutumumabHow we know
- Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerTerminatedPhase 1/2GenmabNCT00677924Written as ZalutumumabHow we know
- Zalutumumab in Head and Neck CancerCompletedPhase 1/2GenmabNCT00093041Written as ZalutumumabHow we know
- DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedPhase 3Danish Head and Neck Cancer GroupNCT00496652Written as ZalutumumabHow we know
- Zalutumumab in Patients With Non-curable Head and Neck CancerCompletedPhase 3GenmabNCT00382031Written as ZalutumumabHow we know
- Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck CancerTerminatedPhase 1/2GenmabNCT00401401Written as zalutumumabHow we know
- Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung CancerTerminatedPhase 2GenmabNCT00460551Written as ZalutumumabHow we know
- Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase InhibitorsWithdrawnPhase 2GenmabNCT01449357Written as zalutumumabHow we know
Codes
What other systems call zalutumumab · ClinicalTrials.gg INT005562
- MeSH (NLM) C546618zalutumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DA709Q5020ZALUTUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q8065569ZalutumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64620ZalutumumabOne source FDA
- DrugBank DB12202One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546618 | zalutumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DA709Q5020 | ZALUTUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8065569 | Zalutumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64620 | Zalutumumab | One source FDA |
| DrugBank | DB12202 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.